Low dystrophin levels in heart can delay heart failure in mdx mice

Journal of Molecular and Cellular Cardiology

Volumn 69, Issue , 2014, Pages 17-23

  Van Putten, Maaike ^a   Van der Pijl, Elizabeth M ^a   Hulsker, Margriet ^a   Verhaart, Ingrid E C ^a   Nadarajah, Vishna D ^a,b   van der Weerd, Louise ^a   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

BMD; Cardiomyopathy; DMD; Dystrophin; Magnetic resonance imaging; Mouse models; Therapy

Indexed keywords

DYSTROPHIN; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; C57BL MOUSE; COMPLICATION; FIBROSIS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DYSTROPHIN; FEMALE; FIBROSIS; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84895467976     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.009     Document Type: Article

References (40)

1. Muntoni F., Torelli S., Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740.
2. Nigro G., Comi L.I., Politano L., Bain R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26:271-277.
3. Connuck D.M., Sleeper L.A., Colan S.D., Cox G.F., Towbin J.A., Lowe A.M., et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008, 155:998-1005.
4. van Bockel E.A., Lind J.S., Zijlstra J.G., Wijkstra P.J., Meijer P.M., van den Berg M.P., et al. Cardiac assessment of patients with late stage Duchenne muscular dystrophy. Neth Heart J 2009, 17:232-237.
5. Gulati S., Saxena A., Kumar V., Kalra V. Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 2005, 72:389-393.
6. Kaspar R.W., Allen H.D., Ray W.C., Alvarez C.E., Kissel J.T., Pestronk A., et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet 2009, 2:544-551.
7. Melacini P., Fanin M., Danieli G.A., Villanova C., Martinello F., Miorin M., et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996, 94:3168-3175.
8. Hoogerwaard E.M., Bakker E., Ippel P.F., Oosterwijk J.C., Majoor-Krakauer D.F., Leschot N.J., et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999, 353:2116-2119.
9. Bowles D.E., McPhee S.W., Li C., Gray S.J., Samulski J.J., Camp A.S., et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012, 20:443-455.
10. Malik V., Rodino-Klapac L.R., Viollet L., Wall C., King W., Al-Dahhak R., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010, 67:771-780.
11. Skuk D., Goulet M., Roy B., Piette V., Cote C.H., Chapdelaine P., et al. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 2007, 17:38-46.
12. Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378:595-605.
13. Goemans N.M., Tulinius M., van den Akker J.T., Burm B.E., Ekhart P.F., Heuvelmans N., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011, 364:1513-1522.
14. Heemskerk H.A., de Winter C.L., de Kimpe S.J., van Kuik-Romeijn P., Heuvelmans N., Platenburg G.J., et al. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009, 11:257-266.
15. Malerba A., Boldrin L., Dickson G. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 2011, 21:293-298.
16. Wu B., Xiao B., Cloer C., Shaban M., Sali A., Lu P., et al. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther 2011, 19:576-583.
17. Jearawiriyapaisarn N., Moulton H.M., Sazani P., Kole R., Willis M.S. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 2010, 85:444-453.
18. Quinlan J.G., Hahn H.S., Wong B.L., Lorenz J.N., Wenisch A.S., Levin L.S. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004, 14:491-496.
19. Spurney C.F., Knoblach S., Pistilli E.E., Nagaraju K., Martin G.R., Hoffman E.P. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008, 18:371-381.
20. Costas J.M., Nye D.J., Henley J.B., Plochocki J.H. Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. Muscle Nerve 2010, 42:881-885.
21. van Erp C., Loch D., Laws N., Trebbin A., Hoey A.J. Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 2010, 42:504-513.
22. Crisp A., Yin H., Goyenvalle A., Betts C., Moulton H.M., Seow Y., et al. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 2011, 20:413-421.
23. Wasala N.B., Bostick B., Yue Y., Duan D. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet 2013, 22:2634-2641.
24. Bostick B., Yue Y., Lai Y., Long C., Li D., Duan D. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008, 19:851-856.
25. Bostick B., Shin J.H., Yue Y., Duan D. AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther 2011, 19:1826-1832.
26. Bostick B., Yue Y., Long C., Duan D. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008, 102:121-130.
27. Newall A.E., Duthie S., Formstone E., Nesterova T., Alexiou M., Johnston C., et al. Primary non-random X inactivation associated with disruption of Xist promoter regulation. Hum Mol Genet 2001, 10:581-589.
28. van Putten M., Hulsker M., Nadarajah V.D., van Heiningen S.H., van Huizen E., van Iterson M., et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One 2012, 7:e31937.
29. van der Geest R.J., Reiber J.H. Quantification in cardiac MRI. J Magn Reson Imaging 1999, 10:602-608.
30. Verhaart I.E., van Duijn R.J., den Adel B., Roest A.A., Verschuuren J.J., Aartsma-Rus A., et al. Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. Neuromuscul Disord 2011, 22(5):418-426.
31. Zhang W., ten Hove M., Schneider J.E., Stuckey D.J., Sebag-Montefiore L., Bia B.L., et al. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study. J Mol Cell Cardiol 2008, 45:754-760.
32. Au C.G., Butler T.L., Sherwood M.C., Egan J.R., North K.N., Winlaw D.S. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011, 92:57-65.
33. Li W., Liu W., Zhong J., Yu X. Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. J Cardiovasc Magn Reson 2009, 11:40.
34. van Putten M., Hulsker M., Young C., Nadarajah V.D., Heemskerk H., van der Weerd L., et al. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J 2013, 27:2484-2495.
35. Bia B.L., Cassidy P.J., Young M.E., Rafael J.A., Leighton B., Davies K.E., et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999, 31:1857-1862.
36. Matsumura T., Saito T., Fujimura H., Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev 2007, 29:496-501.
37. Buyse G.M., Van der Mieren G., Erb M., D'hooge J., Herijgers P., Verbeken E., et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009, 30:116-124.
38. Schade van Westrum S., Dekker L., de Haan R., Endert E., Ginjaar I., de Visser M., et al. Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers. BMC Neurol 2013, 13:88.
39. Bostick B., Yue Y., Duan D. Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy. Muscle Nerve 2010, 42:600-603.
40. Mourkioti F., Kustan J., Kraft P., Day J.W., Zhao M.M., Kost-Alimova M., et al. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol 2013 Aug, 15(8):895-904.